Previous 10 | Next 10 |
home / stock / nrx:cc / nrx:cc news
NurExone Biologic Inc. (NRX:CA) is expected to report $-0.03 for Q3 2023
2023-11-07 16:00:06 ET There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock price of a company increased by 3.36% after the announc...
2023-10-31 15:57:33 ET Some investors only pay attention to fundamentals. Others put more weight on technical charts. Another way of looking at it is to think of technical as being useful for quick decisions for those good at technical analysis, while fundamentals can be beneficial for a de...
2023-10-30 13:16:23 ET Classification as an %OrphanDrug incentivizes and supports the development of certain treatments, increasing access to therapies for rare diseases and providing significant benefits, including market exclusivity, regulatory assistance and financial incentives. ...
TORONTO and HAIFA, Israel, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Or...
TORONTO and HAIFA, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with t...
TORONTO and HAIFA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy (“ ExoTherapy ”) f...
TORONTO and HAIFA, Israel, Oct. 05, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with t...
2023-10-04 16:06:31 ET An estimated 250,000-500,000 people experience a %SpinalCordInjury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined to a wheelchair. What if there were a way to repair the dam...
TORONTO and HAIFA, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal ...
News, Short Squeeze, Breakout and More Instantly...
NurExone Biologic Inc. Company Name:
NRX:CC Stock Symbol:
TSXVC Market:
NurExone Biologic Inc. Website:
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce the preliminary results from a small-scale cont...
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is pleased to announce two significant updates aimed at ad...
TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore the...